\u00df-blocker therapy possibly associated with unusual dreams, insomnia, and sleep disorders<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, March 15, 2021 (HealthDay News) — There seems to be no association between \u009f-blocker therapy and depression, according to a study published online March 15 in Hypertension<\/em>.<\/p>\n Thomas G. Riemer, M.D., Ph.D., from Humboldt-Universit \u00a4t zu Berlin, and colleagues conducted a systematic review and meta-analysis of data from double-blind, randomized controlled trials to assess the risk for psychiatric adverse events (PAEs) or withdrawal of therapy due to PAEs related to the use of \u009f-blockers. Odds ratios were calculated for individual PAEs and withdrawal rates for \u009f-blockers versus placebo or other active treatment. Data were included for 285 eligible studies with 53,533 patients.<\/p>\n In 79 percent of the studies, the risk for bias was determined to be high. The researchers found that depression was the most frequently reported PAE, with a total of 1,600 cases, but it did not occur more commonly during \u009f-blocker treatment versus placebo (odds ratio, 1.02; 95 percent confidence interval, 0.83 to 1.25). There was no association seen for \u009f-blocker use with withdrawal for depression (odds ratio, 0.97; 95 percent confidence interval, 0.51 to 1.84). For comparisons against active agents, results were similar. Only unusual dreams, insomnia, and sleep disorders were possibly related to \u009f-blocker therapy among other PAEs.<\/p>\n “The possible mental health side effects of \u009f-blockers have been the subject of discussion in the scientific community for many decades,” a coauthor said in a statement. “So, our results showing \u009f-blockers are not the cause of so many of these negative side effects are quite consequential.”<\/p>\n One author disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n